8-K: Owens & Minor Pivots to Home-Based Care Amid Q3 Losses

Owens & Minor reported Q3 2025 financial results, including significant net losses, while reaffirming its strategic pivot to a pure-play home-based care business.

Summary

• Owens & Minor reported a net loss of $150.3 million for Q3 2025, significantly wider than the $12.8 million net loss in Q3 2024.
• The company signed a definitive agreement for the sale of its Products & Healthcare Services segment, positioning itself as a pure-play home-based care business.
• Loss from discontinued operations, net of tax, was $144.7 million in Q3 2025, compared to $14.0 million in Q3 2024.
• For the nine months ended September 30, 2025, the net loss was $1.04 billion, compared to $66.6 million in the prior year period.
• Continuing operations revenue increased to $697.3 million in Q3 2025 from $686.8 million in Q3 2024.
• Adjusted net income from continuing operations decreased to $19.9 million ($0.25 per share) in Q3 2025 from $28.2 million ($0.36 per share) in Q3 2024.
• Adjusted EBITDA from continuing operations was $92.2 million in Q3 2025, down from $107.7 million in Q3 2024.
• The company reaffirmed its full-year 2025 financial guidance for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, adjusted EPS between $1.02 and $1.07, and adjusted EBITDA between $376 million and $382 million.
• The nine months ended September 30, 2025, included a $80 million transaction breakage fee for the terminated Rotech acquisition and a $771.6 million loss on classification to held for sale related to discontinued operations.

Sentiment

Score: 4

Explanation: The sentiment is mixed, leaning slightly negative due to substantial reported net losses and one-time charges related to discontinued operations and a terminated acquisition. While the strategic pivot to home-based care is a positive long-term move, the immediate financial impact is significant. The reaffirmation of guidance for continuing operations provides some stability for the core business.

Positives

• The company is strategically pivoting to focus entirely on the home-based care space, which is identified as an attractive growth area.
• A nationwide preferred provider partnership agreement was recently announced, demonstrating focus on growth within the Patient Direct platform.
• The strategic shift aims to create a simpler, stronger company better positioned to serve patients with chronic conditions in the home.
• Full-year 2025 financial guidance for continuing operations was reaffirmed, indicating stability and confidence in the core Patient Direct business.
• Year-to-date 2025 adjusted net income from continuing operations increased to $63.6 million from $50.1 million in YTD 2024.
• Year-to-date 2025 adjusted EBITDA from continuing operations increased to $284.8 million from $268.0 million in YTD 2024.

Negatives

• Reported a significant net loss of $150.3 million in Q3 2025, compared to a net loss of $12.8 million in Q3 2024.
• Loss from discontinued operations, net of tax, was $144.7 million in Q3 2025, a substantial increase from $14.0 million in Q3 2024.
• GAAP loss from continuing operations, net of tax, was $5.6 million in Q3 2025, a decline from income of $1.3 million in Q3 2024.
• Adjusted net income from continuing operations decreased to $19.9 million in Q3 2025 from $28.2 million in Q3 2024.
• Adjusted EBITDA from continuing operations decreased to $92.2 million in Q3 2025 from $107.7 million in Q3 2024.
• The company incurred an $80 million transaction breakage fee for the terminated Rotech acquisition in the nine months ended September 30, 2025.
• A substantial loss on classification to held for sale of $771.6 million was recognized for discontinued operations in the nine months ended September 30, 2025.

Risks

• Future prospects and performance, including financial performance and 2025 financial results, may differ from expectations.
• The anticipated sale of the Products & Healthcare Service business may not be consummated in a timely manner or at all.
• The performance of the business following the completion of the anticipated sale is subject to uncertainties.
• Cost saving initiatives, future indebtedness, and growth may not materialize as projected.
• Industry trends could adversely affect business outcomes.
• The company's ability to address macro and market conditions may impact results.
• Known and unknown risks and uncertainties could cause actual results to differ materially from forward-looking statements.

Future Outlook

The company reaffirmed its full-year 2025 financial guidance for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, adjusted EPS ranging from $1.02 to $1.07, and adjusted EBITDA between $376 million and $382 million. Management anticipates becoming a simpler, stronger company focused on the long-term growth opportunities within home-based care, with capital deployment and strategic direction unified to drive sustainable growth and long-term value creation.

Management Comments

• "Our recent announcement on the sale of our Products & Healthcare Services segment is another meaningful step in our strategy to pivot our focus to the more attractive home-based care space."
• "We are keenly focused on reshaping our organization as one built around our Patient Direct platform and the long-term growth opportunities within home-based care."
• "An example of this focus on growth is our recently announced nationwide preferred provider partnership agreement."
• "Looking ahead, we will be a simpler, stronger company that is better positioned to execute on our mission of serving patients with chronic conditions in the home and are excited about the next chapter for our business."
• "We are confident that the breadth of our offerings and our nationwide reach provide a unique capability to succeed in the future of home-based care."
• "With our focus now centered entirely on Patient Direct, our capital deployment, strategic direction, and execution are unified to drive sustainable growth and long-term value creation."

Industry Context

The strategic pivot towards a pure-play home-based care business aligns with broader healthcare trends emphasizing patient care outside traditional hospital settings. As populations age and chronic conditions become more prevalent, demand for home-based care services is expected to grow. This move positions Owens & Minor to capitalize on this expanding market, differentiating itself from competitors that may have more diversified or hospital-centric portfolios. The divestiture of the Products & Healthcare Services segment suggests a belief that the home-based care segment offers superior long-term growth and profitability prospects compared to its traditional product and service offerings.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the performance against global benchmarks. The focus is on internal strategic realignment and financial performance of continuing and discontinued operations.

Legal Proceedings

• Litigation and related charges, including settlement costs and related charges of certain legal matters, were $1.8 million for Q3 2025 and $2.2 million for YTD 2025.

Stakeholder Impact

• Shareholders face significant immediate losses due to discontinued operations and the Rotech termination, but may benefit from the long-term strategic focus on home-based care.
• Employees in the divested Products & Healthcare Services segment will be impacted by the sale.
• Customers of the Patient Direct segment may see enhanced focus and offerings in home-based care.
• Creditors may view the strategic streamlining as a positive for long-term stability, despite immediate financial hits.

Next Steps

• Complete the sale of the Products & Healthcare Services segment.
• Continue to reshape the organization around the Patient Direct platform.
• Execute on the mission of serving patients with chronic conditions in the home.
• Drive sustainable growth and long-term value creation through unified capital deployment and strategic direction.
• Host an investor conference call on October 30, 2025, at 5:00 p.m. EDT to discuss third quarter 2025 financial results.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation by divesting its Products & Healthcare Services segment to become a pure-play home-based care business. While this pivot offers long-term growth potential in an attractive market, the immediate financial results include substantial net losses and one-time charges related to discontinued operations and a terminated acquisition. The reaffirmation of full-year guidance for the continuing operations provides some confidence in the core business. For existing investors, holding the stock allows observation of the execution of this strategic shift and the performance of the focused home-based care segment. New investors might wait for clearer signs of profitability and successful integration post-divestiture before committing capital.

Keywords

Home-based care, Patient Direct, Healthcare solutions, Medical distribution, SEC filing, Financial results, Strategic pivot, Divestiture, Q3 earnings, OMI